Could the only drug approved to prevent preterm birth be taken off the market?  An FDA advisory panel has narrowly voted to recommend this for Makena. Read how panel members agonized over the decision and felt the data “were at best conflicting.”

The California Preterm Birth Initiative will be watching the progress of the FDA's decision closely over the upcoming months.  

Read the full news story

FDA advisors recommend yanking approval of preterm birth prevention drug after it flops in crucial study